A spokesman for Indonesia's COVID-19 taskforce said the country will continue to prescribe two anti-malaria drugs for coronavirus patients but monitor their use closely, as reported in This is Money.
The World Health Organization (WHO) announced this week it was temporarily halting its global Solidarity Trial, which was testing hydroxychloroquine in more than 30 countries, including Indonesia.
Indonesia has since late March recommended that chloroquine and its derivative, hydroxychloroquine, be widely administered, including to COVID-19 patients with moderate-to-severe symptoms.
In an advisory sent by the WHO to Indonesia's health ministry, the global health body said use of the drugs should be suspended "for treating any COVID-19 patients outside the trial."
Wiku Adismasmito, from Indonesia's COVID-19 national taskforce, said Indonesia would comply with the advice in relation to the trial, but continue general use under strict monitoring.
He said Indonesia would wait for further advice from the WHO in regard to the safety of the drugs, expected in mid-June.
To read more NewsPoints articles, click here.